- Home
- REFI vs AQST Comparison
REFI vs AQST Comparison
Compare REFI & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- AQST
- Stock Information
- Founded
- REFI 2021
- AQST 2004
- Country
- REFI United States
- AQST United States
- Employees
- REFI N/A
- AQST N/A
- Industry
- REFI Real Estate Investment Trusts
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- AQST Health Care
- Exchange
- REFI Nasdaq
- AQST Nasdaq
- Market Cap
- REFI 304.4M
- AQST 272.9M
- IPO Year
- REFI 2021
- AQST 2018
- Fundamental
- Price
- REFI $14.14
- AQST $3.25
- Analyst Decision
- REFI Strong Buy
- AQST Strong Buy
- Analyst Count
- REFI 3
- AQST 6
- Target Price
- REFI $20.00
- AQST $10.67
- AVG Volume (30 Days)
- REFI 82.6K
- AQST 1.6M
- Earning Date
- REFI 08-06-2025
- AQST 08-05-2025
- Dividend Yield
- REFI 13.26%
- AQST N/A
- EPS Growth
- REFI N/A
- AQST N/A
- EPS
- REFI 1.88
- AQST N/A
- Revenue
- REFI $56,790,054.00
- AQST $54,228,000.00
- Revenue This Year
- REFI $15.53
- AQST N/A
- Revenue Next Year
- REFI $6.70
- AQST $45.71
- P/E Ratio
- REFI $7.54
- AQST N/A
- Revenue Growth
- REFI 4.68
- AQST 5.29
- 52 Week Low
- REFI $12.76
- AQST $2.12
- 52 Week High
- REFI $16.47
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- REFI 44.97
- AQST 54.57
- Support Level
- REFI $13.96
- AQST $3.20
- Resistance Level
- REFI $14.62
- AQST $3.61
- Average True Range (ATR)
- REFI 0.30
- AQST 0.28
- MACD
- REFI -0.01
- AQST -0.00
- Stochastic Oscillator
- REFI 27.30
- AQST 50.44
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.